Proton pump inhibitors and their drug interactions: an evidence-based approach

被引:61
作者
Gerson, LB [1 ]
Triadafilopoulos, G [1 ]
机构
[1] Stanford Univ, Med Ctr, Sch Med, Div Gastroenterol, Stanford, CA 94305 USA
关键词
CYP450; drug interactions; lansoprazole; omeprazole; pantoprazole; proton pump inhibitors; rebeprazole;
D O I
10.1097/00042737-200105000-00025
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
The proton pump inhibitors (PPIs) are the most effective antisecretory agents used to treat acid-related disorders, As such, they are frequently prescribed for patients who are concurrently using other medications, PPIs may interact with other drugs through numerous mechanisms. The most important include competitive inhibition of hepatic cytochrome P (CYP) 450 enzymes involved in drug metabolism, and alteration of the absorption of other drugs via changes in gastric pH levels, Poor metabolizers, who lack CYP2C19, may be particularly predisposed to drug interactions, Although the potential for drug interactions is high, few clinically significant interactions have been reported for the PPIs, Nevertheless, caution is indicated when certain drugs are co-prescribed with these agents, The incidence of clinically significant drug interactions increases proportionately with the number of drugs taken and with the age of the patient, The drug interaction with the greatest clinical importance is the reduction in benzodiazepine clearance by omeprazole, Eur J Gastroenterol Hepatol 13:611-616 (C) 2001 Lippincott Williams & Wilkins.
引用
收藏
页码:611 / 616
页数:6
相关论文
共 73 条
[1]  
AHMAD S, 1991, SOUTHERN MED J, V84, P674
[2]  
Anastasio GD, 1997, AM FAM PHYSICIAN, V56, P883
[3]   A STUDY OF THE INTERACTION BETWEEN OMEPRAZOLE AND PHENYTOIN IN EPILEPTIC PATIENTS [J].
ANDERSSON, T ;
LAGERSTROM, PO ;
UNGE, P .
THERAPEUTIC DRUG MONITORING, 1990, 12 (04) :329-333
[4]   EFFECT OF OMEPRAZOLE AND CIMETIDINE ON PLASMA DIAZEPAM LEVELS [J].
ANDERSSON, T ;
ANDREN, K ;
CEDERBERG, C ;
EDVARDSSON, G ;
HEGGELUND, A ;
LUNDBORG, P .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1990, 39 (01) :51-54
[5]   EFFECT OF OMEPRAZOLE TREATMENT ON DIAZEPAM PLASMA-LEVELS IN SLOW VERSUS NORMAL RAPID METABOLIZERS OF OMEPRAZOLE [J].
ANDERSSON, T ;
CEDERBERG, C ;
EDVARDSSON, G ;
HEGGELUND, A ;
LUNDBORG, P .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1990, 47 (01) :79-85
[6]   IDENTIFICATION OF HUMAN LIVER CYTOCHROME-P450 ISOFORMS MEDIATING SECONDARY OMEPRAZOLE METABOLISM [J].
ANDERSSON, T ;
MINERS, JO ;
VERONESE, ME ;
BIRKETT, DJ .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1994, 37 (06) :597-604
[7]   SLOW OMEPRAZOLE METABOLIZERS ARE ALSO POOR S-MEPHENYTOIN HYDROXYLATORS [J].
ANDERSSON, T ;
REGARDH, CG ;
DAHLPUUSTINEN, ML ;
BERTILSSON, L .
THERAPEUTIC DRUG MONITORING, 1990, 12 (04) :415-416
[8]   GEOGRAPHICAL INTERRACIAL DIFFERENCES IN POLYMORPHIC DRUG OXIDATION - CURRENT STATE OF KNOWLEDGE OF CYTOCHROMES P450 (CYP) 2D6 AND 2C19 [J].
BERTILSSON, L .
CLINICAL PHARMACOKINETICS, 1995, 29 (03) :192-209
[9]  
Bliesath H, 1996, INT J CLIN PHARM TH, V34, P152
[10]  
Bliesath H, 1996, INT J CLIN PHARM TH, V34, P51